Literature DB >> 35023121

Craniofacial and Neurological Phenotype in a Case of Oculodentodigital Syndrome.

Christos Yapijakis1,2,3, Stefania Kalogera4, Antonia Angelopoulou4, Georgios Paraskevas5, Elisabeth Kapaki5.   

Abstract

INTRODUCTION: Oculodentodigital syndrome (ODDS) is a rare genetic disorder caused by mutations in the gap junction GJA1 gene encoding connexin-43 (chromosome 6q22). A typical ODDS case is presented.
MATERIAL AND METHODS: A 40-year-old male patient was examined neurologically and genetically. He had a history of recent parieto-occipital leukodystrophy, some episodes of temporary hearing loss, and characteristic facial features of ODDS. Sequencing of the GJA1 gene was performed in patient's total genomic DNA sample isolated from peripheral blood cells.
RESULTS: A novel heterozygous missense mutation (443G>A) was identified in the GJA1 gene, resulting in coding for a different amino acid (Arg148Gln).
CONCLUSION: The molecular genetic analysis confirmed the diagnosis of ODDS. The novel mutation, located within a calmodulin binding region of connexin-43, probably affects proper channel function.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Connexin-43; Hearing loss; Leukodystrophy; Oculodentodigital syndrome

Mesh:

Year:  2021        PMID: 35023121     DOI: 10.1007/978-3-030-78787-5_39

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

Review 1.  Oculodentodigital Dysplasia with a Novel Mutation in GJA1 Diagnosed by Targeted Gene Panel Sequencing: A Case Report and Literature Review.

Authors:  Jaeyoung Choi; Aram Yang; Ari Song; Minji Lim; Jinsup Kim; Ja-Hyun Jang; Ki-Tae Park; SungYoon Cho; Dong-Kyu Jin
Journal:  Ann Clin Lab Sci       Date:  2018-11       Impact factor: 1.256

Review 2.  Neurological manifestations of oculodentodigital dysplasia: a Cx43 channelopathy of the central nervous system?

Authors:  Marijke De Bock; Marianne Kerrebrouck; Nan Wang; Luc Leybaert
Journal:  Front Pharmacol       Date:  2013-09-26       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.